Sidley Represents Lead Investors in US$200 Million Financing by NiKang Therapeutics
June 3, 2021
联系方式
办公室
随时了解最新情况
Sidley is representing the lead investors in NiKang Therapeutics Inc.’s US$200 million equity financing pursuant to the issuance and sale of its Series C Preferred Stock. The lead investors were HBM Healthcare Investments, Cormorant Asset Management, and Octagon Capital Advisors with participation from a syndicate of other leading institutional investors. NiKang is a clinical-stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet medical needs.
The Sidley team is led by Mehdi Khodadad (M&A and Private Equity) and includes Anthony Friedman, Patrick Sims, and Max Chaffetz (M&A and Private Equity).